Recent Developments in Microbiome Therapeutics Recent-Developments-in-Microbiome-Therapeutics-Nov

Table 1: Overview of start-ups Company Location USA Evelo Biosciences USA Second Genome USA AOBiome Therapeutics Disease Indications Prevention of Dental Caries C3J Therapeutics Vedanta Biosciences Funding to date USA USA $105,000,000 C. difficile Infection Lead Candidate Preclinical Clinical Phase 1 Phase 2 Phase 3 CD17 – $85,000,000 Cancer, Immuno-inflammatory diseases – $62,900,000 Inflammatory Bowel Disease SGM-1019 C. difficile Infection VE 303 Inflammatory Bowel Disease VE 202 Immuno-oncology VE 505 Mild to moderate acne B244 Hypertension B244 Allergic rhinitis B244 Pruritis/Eczema – Wound healing – Thermoregulation – $38,706,513 Discovery C16G2 Obesity, IBD, Autoimmune disease $55,400,000 Stage of Development Recurrent C. difficile Infection VRE Elimination Pediatric Ulcerative Colitis Rebiotix Enterome Bioscience Evolve Biosystems 16 USA France USA $36,295,000 $34,270,000 $29,000,000 Multi-Drug Resistant UTI RBX2660 (Enema Formulation) Hepatic Encephalopathy Recurrent C. difficile Infection RBX7455 (Oral Formulation) Crohn’s Disease EB8018 Crohn’s Disease EB110, EB220 Ulcerative colitis, Irritable Bowel Syndrome EB410, EB420 Glioblastoma EO2315 Unknown EO510, EO520 Infant gut dysbiosis Evivo (commercially available) Recent Developments in Microbiome Therapeutics

Recent Developments in Microbiome Therapeutics Recent-Developments-in-Microbiome-Therapeutics-Nov | Page 16